bmi 25 glp 1 requirements for A Balancing Act: GLP-1 Receptor Agonists Non-Diabetic Obesity – Clinical Correlations Medicare GLP-1 Drug Coverage GLP1-Injections | Hydrations Wellness

Under standard FDA review timelines, a decision is expected in late 2026

[DOI] [PMC free article] [PubMed] [Google Scholar] 47.Baggio LL, Drucker DJ

At Blue Horizon, we believe that navigating these choices requires a clear, evidence-based understanding of how your body works as a whole system

[DOI] [PMC free article] [PubMed] [Google Scholar] 28.Loomba R., Sanyal A.J., Kowdley K.V., Bhatt D.L., Alkhouri N., Frias J.P., Bedossa P., Harrison S.A., Lazas D., Barish R., et al

July 31, 2025 - High Performer Recognition Program In June 2023, we implemented a High Performer Recognition Program within the Quality Care Plus (QCP) incentive program with the goal to acknowledge practice groups that have a commitment to high-quality care

Investigating the same primary endpoint, TRANSCEND-T2D-2 (NCT06260722) will compare retatrutide to semaglutide in people with inadequately controlled T2D (treated with oral glucose-lowering treatments) over 26 months